Focus on therapeutic peptides and their delivery.
Quick Facts
What This Study Found
About 100 peptide drugs have reached clinical approval, with nearly half approved in the past 20 years. The global market may exceed $50 billion.
Key Numbers
~100 approved peptide therapeutics; nearly 50% approved in last 20 years; market projected >$50 billion by 2024
How They Did This
Narrative literature review covering therapeutic peptides, parenteral administration routes, and novel delivery systems.
Why This Research Matters
Peptides sit between small molecules and large biologics, offering a unique balance of specificity, lower toxicity, and simpler manufacturing that drives rapid growth in drug development.
What This Study Doesn't Tell Us
Narrative review without systematic search methodology. Market projections may vary by source. Does not cover every approved peptide individually.
Trust & Context
- Original Title:
- Focus on therapeutic peptides and their delivery.
- Published In:
- International journal of pharmaceutics, 675, 125555 (2025)
- Authors:
- Rosson, E, Lux, F, David, L, Godfrin, Y, Tillement, O, Thomas, E
- Database ID:
- RPEP-13316
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13316APA
Rosson, E; Lux, F; David, L; Godfrin, Y; Tillement, O; Thomas, E. (2025). Focus on therapeutic peptides and their delivery.. International journal of pharmaceutics, 675, 125555. https://doi.org/10.1016/j.ijpharm.2025.125555
MLA
Rosson, E, et al. "Focus on therapeutic peptides and their delivery.." International journal of pharmaceutics, 2025. https://doi.org/10.1016/j.ijpharm.2025.125555
RethinkPeptides
RethinkPeptides Research Database. "Focus on therapeutic peptides and their delivery." RPEP-13316. Retrieved from https://rethinkpeptides.com/research/rosson-2025-focus-on-therapeutic-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.